Wall Street analysts predict that Integra LifeSciences Holdings Co. (NASDAQ:IART) will post $374.48 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Integra LifeSciences’ earnings, with estimates ranging from $371.31 million to $376.70 million. Integra LifeSciences reported sales of $258.67 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 44.8%. The business is scheduled to report its next earnings results on Monday, August 9th.
On average, analysts expect that Integra LifeSciences will report full year sales of $1.53 billion for the current financial year. For the next fiscal year, analysts expect that the business will post sales of $1.62 billion, with estimates ranging from $1.61 billion to $1.64 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Integra LifeSciences.
Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, April 27th. The life sciences company reported $0.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.12. Integra LifeSciences had a return on equity of 14.26% and a net margin of 4.10%. The business had revenue of $360.10 million during the quarter, compared to the consensus estimate of $349.78 million. During the same period in the previous year, the business earned $0.48 EPS. The business’s quarterly revenue was up 1.6% on a year-over-year basis.
A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company boosted their price target on Integra LifeSciences from $68.00 to $74.00 and gave the company an “equal weight” rating in a report on Thursday, April 29th. Truist Financial upped their price objective on Integra LifeSciences from $60.00 to $70.00 in a research note on Wednesday, January 6th. Credit Suisse Group upped their price objective on Integra LifeSciences from $73.00 to $79.00 and gave the stock an “outperform” rating in a research note on Thursday, February 25th. Piper Sandler boosted their price target on Integra LifeSciences from $47.00 to $65.00 and gave the stock a “neutral” rating in a research report on Friday, January 29th. Finally, Citigroup boosted their price target on Integra LifeSciences from $70.00 to $78.00 in a research report on Thursday, April 29th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $71.36.
In related news, SVP Jeffrey Mosebrook sold 1,058 shares of the company’s stock in a transaction on Tuesday, March 2nd. The stock was sold at an average price of $68.70, for a total transaction of $72,684.60. Also, EVP Eric Schwartz sold 2,288 shares of the company’s stock in a transaction on Thursday, February 25th. The shares were sold at an average price of $69.52, for a total value of $159,061.76. Following the transaction, the executive vice president now directly owns 29,409 shares in the company, valued at $2,044,513.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,086,352 shares of company stock valued at $74,379,561. 4.30% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Envestnet Asset Management Inc. raised its position in Integra LifeSciences by 9.3% during the first quarter. Envestnet Asset Management Inc. now owns 55,164 shares of the life sciences company’s stock valued at $3,811,000 after buying an additional 4,672 shares during the period. Victory Capital Management Inc. raised its position in Integra LifeSciences by 93.0% during the first quarter. Victory Capital Management Inc. now owns 16,891 shares of the life sciences company’s stock valued at $1,167,000 after buying an additional 8,138 shares during the period. The Manufacturers Life Insurance Company raised its position in Integra LifeSciences by 18.3% during the first quarter. The Manufacturers Life Insurance Company now owns 309,613 shares of the life sciences company’s stock valued at $21,391,000 after buying an additional 47,902 shares during the period. State of Michigan Retirement System raised its position in Integra LifeSciences by 1.9% during the first quarter. State of Michigan Retirement System now owns 26,266 shares of the life sciences company’s stock valued at $1,815,000 after buying an additional 500 shares during the period. Finally, Virginia Retirement Systems ET AL increased its position in Integra LifeSciences by 6.0% in the 1st quarter. Virginia Retirement Systems ET AL now owns 16,000 shares of the life sciences company’s stock worth $1,105,000 after purchasing an additional 900 shares during the last quarter. 85.71% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ IART traded down $0.11 during trading on Thursday, reaching $73.95. The stock had a trading volume of 331,093 shares, compared to its average volume of 382,011. Integra LifeSciences has a one year low of $42.12 and a one year high of $77.40. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.31 and a current ratio of 4.52. The stock has a market cap of $6.25 billion, a PE ratio of 110.54, a P/E/G ratio of 1.97 and a beta of 1.26. The firm’s 50 day moving average price is $70.23 and its two-hundred day moving average price is $63.40.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Recommended Story: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.